Why Sarepta Therapeutics (SRPT) Is Up 12.7% After FDA Accepts sNDAs Backed By ESSENCE Data
Sarepta Therapeutics' stock rose 12.7% after the FDA accepted supplemental New Drug Applications (sNDAs) for its Duchenne muscular dystrophy (DMD) therapies, AMONDYS 45 and VYONDYS 53, for conversion to traditional approvals. These applications are backed by Phase 3 ESSENCE data and real-world evidence, which could strengthen the foundation of Sarepta's broader DMD franchise, although ELEVIDYS remains a key catalyst and central risk. The recent acceptance of sNDAs offers a more stable outlook for the company's existing DMD treatments.
Enterprise value to EBITDA forward of Sarepta Therapeutics, Inc. – LSE:0L35
This article provides financial data for Sarepta Therapeutics, Inc. (LSE:0L35), specifically focusing on its enterprise value to EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) forward metric. It appears to be a stub or data-point article from TradingView, offering a snapshot of a key financial ratio for the company on the London Stock Exchange. The content highlights the period, value, and change percentages related to this financial indicator.
Price to earnings forward of Sarepta Therapeutics, Inc. – LSE:0L35
This article provides financial information for Sarepta Therapeutics, Inc. (LSE:0L35), specifically focusing on its forward price-to-earnings ratio. The content primarily lists market data sources and disclaimers from TradingView and its partners. It does not provide specific values for the price-to-earnings forward metric.
Enterprise value to EBIT forward of Sarepta Therapeutics, Inc. – LSE:0L35
This article provides financial data for Sarepta Therapeutics, Inc. (LSE:0L35) with a specific focus on its enterprise value to EBIT forward. It is presented in a data-centric format common on financial platforms like TradingView, indicating the period, value, and change metrics for this financial ratio.
SRPT - Sarepta Therapeutics Inc Volatility & Greeks
This article provides a detailed financial overview of Sarepta Therapeutics Inc (SRPT), including its stock performance, key financial metrics, and market volatility data. It lists various ratios, growth rates, insider and institutional ownership, and analyst recommendations. The information presented aims to give a comprehensive snapshot of the company's current financial health and market position.
ETFs Investing in Sarepta Therapeutics, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Sarepta Therapeutics, Inc. It provides detailed information for each ETF, including market value, weight of Sarepta Therapeutics stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The ETFs cover a range of categories such as small-cap, health care, and biotechnology, offering different investment strategies.
If You Invested $1,000 in Sarepta Therapeutics Inc (SRPT)
This article analyzes the historical performance of an investment in Sarepta Therapeutics Inc (SRPT), detailing returns over 1, 5, and 10 years, and comparing them to the S&P 500. It also provides an in-depth company profile, outlining Sarepta's focus on genetic medicines for rare diseases, particularly Duchenne muscular dystrophy, its various therapeutic platforms including gene therapy and exon-skipping, its siRNA pipeline, and its financial and regulatory activities.
SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth
Sarepta Therapeutics (SRPT) stock fell 7% after-hours despite beating Q1 2026 revenue and earnings expectations, primarily due to lower sales of its gene therapy Elevidys. The therapy's sales were impacted by safety concerns and a narrowed addressable patient population. CEO Doug Ingram remains optimistic, predicting a return to growth for Elevidys and an overall stabilization of the company's commercial portfolio.
Sarepta Therapeutics, Inc. Stock 12‑Month Price Target Cut to $22, Implies 14% Upside
Sarepta Therapeutics, Inc. (SRPT) has seen its average 12-month price target reduced from $22.67 to $22 by 23 analysts, despite forecasts ranging from $5 to $38 per share. This new target implies a 14% potential upside based on the July 2 closing price. The consensus rating for SRPT remains "Hold," with 7 "Buy," 14 "Hold," and 7 "Sell" recommendations among 28 covering analysts.
Sarepta Therapeutics Jumps 6.5% Amid Sector-Wide Rally
Sarepta Therapeutics saw its stock surge by 6.5% on Thursday, closing at $19.38 per share amidst a broad sector-wide rally in biotechnology stocks. The gene therapy developer's gain outpaced several peers, fueled by investor rotation into the sector rather than company-specific news. While the rally provided a significant boost, the article notes that investors will need to monitor if this sector momentum continues to sustain Sarepta's gains without new catalysts.
H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $5
H.C. Wainwright has reaffirmed its Sell rating for Sarepta Therapeutics (SRPT.US) and maintained a target price of $5. This indicates a continued bearish outlook on the company's stock by the analytical firm.
Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail
Sarepta Therapeutics has secured an early 2027 FDA decision for full approval of its Duchenne muscular dystrophy exon-skipping therapies, Amondys 45 and Vyondys 53, despite their failure to improve motor function in a confirmatory Phase 3 trial. The FDA's acceptance of the application is seen as a positive signal by analysts, especially given Sarepta's submission includes substantial real-world evidence and favorable safety profiles. This move comes amidst broader changes at the FDA, with analysts suggesting a potentially more lenient regulatory environment for rare diseases.
Sarepta Therapeutics (SRPT) Following FDA Filings And The Case For A Reset Valuation
Sarepta Therapeutics (SRPT) is under renewed scrutiny after the FDA accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53. Despite this regulatory progress, the stock has experienced significant declines over the past 90 days and three years, making investors question if the current low valuation presents a real opportunity or if future growth is already priced in. Analysts, despite varying price targets, generally estimate a fair value of $21.65, suggesting the stock might be undervalued, but P/E ratios hint at potential valuation risks if market sentiment changes.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics, Inc. granted equity awards to 30 new employees in the second quarter of 2026 as a material inducement for their employment. These awards, totaling 151,305 restricted stock units (RSUs), were approved by the Compensation Committee and are in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with one-fourth vesting annually, contingent on continued employment.
FDA Accepts sNDAs for Sarepta's AMONDYS 45 and VYONDYS 53, Targeting Traditional Approval in Duchenne
The FDA has accepted Sarepta's supplemental New Drug Applications (sNDAs) for Amondys 45 and Vyondys 53, aiming to convert their accelerated approvals to traditional approvals for Duchenne muscular dystrophy. The decision is based on data from the Phase 3 ESSENCE confirmatory trial and extensive real-world evidence, with a PDUFA target action date of February 28, 2027. This move, supported by patient advocacy groups, acknowledges the unique challenges of developing treatments for ultra-rare diseases and the importance of real-world data in such cases.
FDA Accepts Sarepta's sNDAs for Casimersen and Golodirsen for Duchenne Muscular Dystrophy
The FDA has accepted Sarepta Therapeutics' supplemental new drug applications (sNDAs) for casimersen (Amondys 45) and golodirsen (Vyondys 53) for Duchenne muscular dystrophy (DMD), setting a PDUFA target action date of February 28, 2027. These submissions aim to convert the existing accelerated approvals to traditional approvals, based on phase 3 ESSENCE study data and extensive real-world evidence. While the ESSENCE trial narrowly missed its primary functional endpoint, it demonstrated statistically significant improvements in dystrophin expression and a favorable safety profile.
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
Sarepta Therapeutics announced that the FDA has accepted supplemental New Drug Applications (sNDAs) for AMONDYS 45® and VYONDYS 53® for Duchenne muscular dystrophy (DMD), with a PDUFA target action date of February 28, 2027. These sNDAs aim to convert the accelerated approvals of these exon-skipping therapies to traditional approvals, supported by data from the ESSENCE study and extensive real-world evidence. The company highlights the significance of this step for the Duchenne community, emphasizing the therapies' role in preserving muscle function and slowing disease progression in an ultra-rare patient population.
FDA Accepts Sarepta's Applications for Full Approval of Two DMD Treatments
The FDA has accepted Sarepta's applications for Amondys 45 and Vyondys 53, setting a target decision date of February 28, 2027, for full approval of these Duchenne muscular dystrophy (DMD) treatments. The applications are supported by clinical and real-world data showing positive trends in protein production and slowed functional decline. Following the announcement, Sarepta's shares rose, despite mixed ratings from analysts regarding the company's long-term performance.
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs
Sarepta Therapeutics is advancing towards full FDA approval for its Duchenne Muscular Dystrophy drugs, VYONDYS 53 and AMONDYS 45. The FDA has accepted supplemental New Drug Applications, setting a target action date of February 28, 2027. This move is supported by data from the Phase 3 ESSENCE study and real-world evidence showing preserved muscle function and slower disease progression in patients treated with these exon-skipping therapies.
FDA accepts Sarepta filings for two Duchenne therapies
Sarepta Therapeutics Inc. announced that the FDA has accepted its supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53, Duchenne muscular dystrophy treatments, for review. The FDA has set a target action date of February 28, 2027, to convert their accelerated approvals to traditional approvals. This decision is supported by data from the ESSENCE confirmatory study, real-world evidence, and safety data.
SRPT Stock Climbs After Sarepta Seeks Permanent FDA Nod For Two Duchenne Therapies
Sarepta Therapeutics' stock rose after the FDA accepted its applications for full, permanent approval of Amondys 45 and Vyondys 53, two Duchenne muscular dystrophy treatments. The FDA has set a target decision date of February 28, 2027, for these drugs, which were initially approved on an accelerated basis. Retail sentiment on Stocktwits shifted to 'bullish' despite the confirmatory study not meeting its primary statistical goal, as the data showed positive trends and no new safety concerns.
FDA to review Sarepta’s Duchenne drugs, with decision due Feb. 28, 2027
Sarepta Therapeutics announced that the FDA has accepted for review its supplemental New Drug Applications (sNDAs) for AMONDYS 45® (casimersen) and VYONDYS 53® (golodirsen), both treatments for Duchenne muscular dystrophy (DMD). The FDA has set a PDUFA target action date of February 28, 2027, for these applications, which aim to convert the drugs' accelerated approvals to traditional approvals. The sNDAs are supported by data from the ESSENCE confirmatory study, published real-world evidence, and favorable safety profiles, highlighting the impact of these exon-skipping therapies on preserving muscle function and slowing disease progression in DMD patients.
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) added to Russell 2000 Index
Sarepta Therapeutics, Inc. (NasdaqGS:SRPT) has been added to the Russell 2000 Index, while also being dropped from several other Russell indices, including the Russell 1000 Index, Russell Midcap Growth Benchmark, Russell 1000 Growth Benchmark, Russell 1000 Dynamic Index, Russell Midcap Index, and Russell 1000 Value Benchmark. The company specializes in RNA-targeted therapeutics, siRNA knockdown therapies, and gene therapy for rare diseases, particularly Duchenne muscular dystrophy.
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 2000 Value Benchmark
Sarepta Therapeutics, Inc. (NasdaqGS:SRPT) has been added to the Russell 2000 Value Benchmark. This move comes as the biopharmaceutical company continues to focus on developing RNA-targeted therapeutics for rare diseases, particularly Duchenne muscular dystrophy. The article also notes recent movements of SRPT in and out of various Russell indices.
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) dropped from Russell 1000 Dynamic Index
Sarepta Therapeutics, Inc. (NasdaqGS:SRPT) has been removed from the Russell 1000 Dynamic Index. This news follows recent reports on the stabilization of their drug Elevidys and increasing importance of their siRNA pipeline, as noted by RBC. The company, a commercial-stage biopharmaceutical firm, focuses on RNA-targeted therapeutics and gene therapy for rare diseases like Duchenne muscular dystrophy.
Sarepta Therapeutics Rises As Gene Therapy Outlook Strengthens
Sarepta Therapeutics Inc. (SRPT) stock rose by 5.49% due to positive FDA-related gene therapy progress, with RBC reports indicating stabilizing Elevidys sales and controlled costs. The stock is currently trading in a range, but the regulatory environment for gene therapy is becoming more supportive, potentially offering a clearer path to cash flow positivity and future catalyst-driven volatility. Analysts see a favorable risk-reward balance despite current thin profitability and negative cash flow.
SRPT Jumps As Sarepta Wins Tailwinds In Gene Therapy
Sarepta Therapeutics Inc. (SRPT) stock rose over 5% due to optimism surrounding positive FDA developments concerning gene therapy, particularly for its Elevidys franchise. RBC analysts note the franchise's stabilization and controlled operating expenses, alongside favorable FDA draft guidance aimed at streamlining cell and gene therapy approvals. The company's financials show strong revenue growth and a solid balance sheet, despite technical indicators suggesting a mildly bearish short-term trend.
Sarepta Therapeutics, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh
This article provides an overview of financial actuals and estimates for Sarepta Therapeutics, Inc. (BMFBOVESPA:S1RP34). It allows users to explore reported financial data and analyst estimates across various financial statements, compare actuals with estimates, and visualize trends. The content explicitly states that it is not investment advice and encourages users to conduct their own research.
How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing
This article analyzes Sarepta Therapeutics Inc. (SRPT) using AI models to provide trading strategies. It highlights a strong near-term sentiment with a neutral mid- and long-term outlook, identifying an exceptional risk-reward setup. The analysis offers specific entry, target, and stop-loss points for position, momentum breakout, and risk hedging strategies.
Sarepta Therapeutics (SRPT) Stock Could Be 19% Undervalued As Elevidys Outlook Steadies
Sarepta Therapeutics (SRPT) stock is currently considered 19% undervalued with a narrative fair value of $21.65, driven by expectations for its gene therapy Elevidys and siRNA programs. However, an alternative earnings-based view suggests the stock is expensive, trading at a P/E of 28.4x compared to the industry average of 16.5x. Investors are encouraged to weigh both valuation perspectives and consider associated risks and potential upsides.
Sarepta Therapeutics (SRPT) Stock Could Be 19% Undervalued As Elevidys Outlook Steadies
Sarepta Therapeutics (SRPT) stock is considered 19% undervalued with a narrative fair value of $21.65, driven by its Elevidys gene therapy and siRNA pipeline. While recent short-term share price momentum is positive, longer-term returns have been weak, and the company still faces risks such as safety concerns for Elevidys and administrative delays. An alternative earnings-based view suggests the stock looks expensive at 28.4x P/E compared to the industry average.
Sarepta Therapeutics (SRPT) Stock Could Be 19% Undervalued As Elevidys Outlook Steadies
Sarepta Therapeutics (SRPT) is seen as potentially 19% undervalued, with its gene therapy Elevidys and siRNA pipeline stabilizing. While the company's stock has faced long-term weakness, recent commentary and analyst targets suggest a potential for upside, focusing on its rare disease treatments. However, an alternative earnings-based view suggests Sarepta is currently overvalued compared to the industry and its estimated fair ratio.
Is Sarepta (SRPT) Quietly Recasting Its Story Around siRNA as Elevidys Awaits Regulators?
Sarepta Therapeutics' future relies on regulatory decisions for its Duchenne muscular dystrophy gene therapy, Elevidys, and the development of its siRNA pipeline. Recent updates suggest a more gene therapy-friendly regulatory environment, bolstering Elevidys as a near-term catalyst. Investors are also focusing on the siRNA platform's potential to broaden Sarepta's pipeline and mitigate risks associated with Elevidys.
Is Sarepta (SRPT) Quietly Recasting Its Story Around siRNA as Elevidys Awaits Regulators?
Sarepta Therapeutics' future is highly dependent on regulatory decisions concerning its Duchenne muscular dystrophy gene therapy, Elevidys, and the development of its siRNA pipeline. Recent updates suggest a more favorable regulatory environment for Elevidys, which could significantly influence Sarepta's investment narrative. The company's projections anticipate a revenue decline but a substantial increase in earnings by 2029, with a potential 24% upside on its current price, while analysts' lower expectations highlight the risks.
Is Sarepta (SRPT) Quietly Recasting Its Story Around siRNA as Elevidys Awaits Regulators?
Sarepta Therapeutics' future hinges on regulatory decisions for its Duchenne muscular dystrophy gene therapy, Elevidys, and the advancement of its siRNA pipeline. Recent data for SRP-1001 and SRP-1003 in rare muscle diseases highlight the potential of the siRNA platform. While a gene therapy-friendly regulatory tone for Elevidys is a near-term catalyst, investors should also consider the broader RNA-based pipeline against regulatory scrutiny and risk factors.
Sarepta Therapeutics options trading jumps to 5,295 contracts
Options trading for Sarepta Therapeutics (NASDAQ: SRPT) significantly increased to 5,295 contracts, with call volume notably higher than put volume. The rise in trading activity coincided with a 9.6% increase in Sarepta shares, reaching $17.30. The company's three-month volatility also saw an increase, suggesting heightened investor interest and market movement.
Sarepta Therapeutics Inc (SRPT) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Sarepta Therapeutics Inc (SRPT), listing its major institutional holders and their respective proportions. It also breaks down shareholder types, showing investment advisors, hedge funds, and individual investors as key categories. Additionally, the article provides historical institutional shareholding data and recent shareholder activity, including changes in holdings by prominent firms.
ING Groep NV Cuts Stock Holdings in Sarepta Therapeutics, Inc. $SRPT
ING Groep NV significantly reduced its stake in Sarepta Therapeutics by 63.7% in the fourth quarter, selling over 153,000 shares. Despite this, other institutional investors like Vanguard and First Trust Advisors increased their holdings, maintaining high overall institutional ownership at 86.68%. Analyst sentiment is generally cautious with a "Hold" rating, though Sarepta recently surpassed EPS and revenue expectations.
Is Sarepta Therapeutics (SRPT) Quietly Rewriting Its Risk Profile With New Equity Plans And Q1 Profitability?
Sarepta Therapeutics recently filed a US$341.998057 million shelf registration and approved new equity plans, while returning to profitability in Q1 2026 despite weaker ELEVIDYS sales. These actions aim to enhance financial flexibility and employee ownership, supporting a self-funded pipeline amid ongoing scrutiny over ELEVIDYS safety and treatment bottlenecks. The company's disciplined cost control and profitability provide a buffer against potential volatility, though future performance hinges on expanding ELEVIDYS use and advancing its drug pipeline.
BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors
BioGene Therapeutics Inc. has appointed Ty Howton to its Board of Directors, effective immediately. Mr. Howton brings nearly 30 years of biopharmaceutical industry experience, including executive roles at Vertex Pharmaceuticals, Sarepta Therapeutics, and Solid Biosciences, with a strong background in operations, legal, financing, and governance. The Company has granted Mr. Howton stock options and restricted share units as part of his appointment.
Sarepta (SRPT) grants director 16,875 RSUs with one-year vesting
Sarepta Therapeutics, Inc. director Deirdre P. Connelly was granted 16,875 Restricted Stock Units (RSUs) as compensation, increasing her direct holdings to 22,100 shares. The RSUs have a vesting period until the earlier of one year from the grant date or the next annual shareholder meeting. This transaction was a stock-based compensation award rather than an open-market purchase by the director.
A Look At Sarepta Therapeutics (SRPT) Valuation After New Shelf Registration For Potential Share Offering
Sarepta Therapeutics (SRPT) has filed a shelf registration for up to US$342 million in common shares, raising questions about its valuation. Despite a significant stock price drop, analysts estimate it is currently 27.3% undervalued at $15.75, with a fair value target of $21.65. This valuation relies on future earnings growth, successful development of new programs, and higher profit margins, assuming no further safety concerns or data quality issues.
Sarepta (SRPT) director gets 16,875 RSUs vesting after one year
Sarepta Therapeutics director Stephen Mayo was awarded 16,875 Restricted Stock Units (RSUs) of common stock at no purchase price. These RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual stockholders' meeting that is at least 50 weeks after the prior year's meeting. Following this grant, Mayo directly holds 18,640 shares of Sarepta common stock.
Improving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to Buy
Sarepta Therapeutics Inc. (SRPT) has become a focus as one of the most shorted small-cap stocks to buy due to its improved profitability. Despite a slight revenue decline attributed to updated labeling for its gene therapy ELEVIDYS, the company achieved a non-GAAP net income of $385.4 million in Q1, bouncing back from a net loss in the prior year. This financial turnaround, driven by cost management and a favorable revenue mix, positions SRPT to fund its pipeline without additional debt.
A Look At Sarepta Therapeutics (SRPT) Valuation After New Shelf Registration For Potential Share Offering
Sarepta Therapeutics (SRPT) has filed a shelf registration for up to US$342 million in common shares, raising questions about its valuation after a significant share price decline. Despite the stock being down over 63% in the last year, a narrative fair value estimates it as 27.3% undervalued at $21.65, compared to its current price of $15.75. This valuation depends on addressing safety concerns and maintaining earnings assumptions for its rare disease pipeline.
Sarepta (SRPT) director receives 16,875 RSUs in stock grant
Sarepta Therapeutics director Kathleen M. Behrens was granted 16,875 restricted stock units (RSUs) as compensation, not through an open-market trade. These RSUs will vest on the earlier of the one-year anniversary of the grant date or the next qualifying annual meeting. Following this grant, Behrens directly holds 214,357 shares of common stock, with an additional 10,000 shares held indirectly by a trust.
Sarepta (SRPT) awards director Barry Richard 16,875 RSUs
Sarepta Therapeutics, Inc. (SRPT) director Barry Richard was granted 16,875 Restricted Stock Units (RSUs) at a price of $0.00 per share. These RSUs will vest on the earlier of one year from the grant date or the next annual stockholders' meeting that is at least 50 weeks after the prior year's meeting. Following this grant, Richard directly holds 2,983,542 shares of Sarepta common stock, with additional indirect holdings through an LLC and a trust.
Sarepta Therapeutics (SRPT) director receives 16,875-share RSU equity award
Sarepta Therapeutics director Michael Andrew Chambers was granted an equity award of 16,875 Restricted Stock Units (RSUs) at no cash cost per share. These RSUs will vest on the earlier of one year from the grant date or the next annual stockholders' meeting, provided it meets specific timing conditions. Following this grant, Chambers directly holds 27,535 shares and indirectly holds 476,492 shares through a revocable trust, as detailed in the Form 4 filing.
Sarepta Shareholders Approve 2026 Equity and ESPP Plans
Sarepta Therapeutics (SRPT) shareholders approved a new 2026 Equity Incentive Plan and a 2026 Employee Stock Purchase Plan, replacing previous versions and authorizing a significant number of shares for awards and employee purchases. Additionally, shareholders re-elected five Class I directors, supported 2025 executive compensation, and ratified KPMG LLP as the independent auditor. These approvals aim to strengthen talent retention, align with strategic direction, and ensure governance continuity, with analysts currently rating SRPT as a "Hold" due to volatile financial performance despite strong margins.
Sarepta Therapeutics Adopts 2026 Equity Incentive and Employee Stock Purchase Plans – 8-K SEC Filing Summary
Sarepta Therapeutics (NASDAQ: SRPT) held its 2026 annual shareholders meeting, where key governance and compensation decisions were made. Shareholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan, which are crucial for attracting and retaining talent. Additionally, executive compensation was approved on an advisory basis, and KPMG LLP was ratified as the independent auditor.
